Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosaHAGIHARA, Mao; KUTI, Joseph L; NICOLAU, David P et al.Diagnostic microbiology and infectious disease. 2012, Vol 72, Num 3, pp 258-262, issn 0732-8893, 5 p.Article

Validation of the Infectious Diseases Society of America/ American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniaeKONTOU, Paschalina; KUTI, Joseph L; NICOLAU, David P et al.The American journal of emergency medicine. 2009, Vol 27, Num 8, pp 968-974, issn 0735-6757, 7 p.Article

Probability of Pharmacodynamic Target Attainment With Standard and Prolonged-Infusion Antibiotic Regimens for Empiric Therapy in Adults With Hospital-Acquired PneumoniaKIM, Aryun; KUTI, Joseph L; NICOLAU, David P et al.Clinical therapeutics. 2009, Vol 31, Num 11, pp 2765-2778, issn 0149-2918, 14 p.Article

Development of an HPLC Method for the Determination of Anidulafungin in Human Plasma and SalineSUTHERLAND, Christina A; NICOLAU, David P; KUTI, Joseph L et al.Journal of chromatographic science. 2011, Vol 49, Num 5, pp 397-400, issn 0021-9665, 4 p.Article

Population Pharmacokinetics of Piperacillin/Tazobactam in Critically III Young ChildrenCIES, Jeffrey J; SHANKAR, Venkat; SCHLICHTING, Christine et al.The Pediatric infectious disease journal. 2014, Vol 33, Num 2, pp 168-173, issn 0891-3668, 6 p.Article

Risk Factors and Outcomes Associated with Isolation of Meropenem High-Level-Resistant Pseudomonas aeruginosaEAGYE, Kathryn J; KUTI, Joseph L; NICOLAU, David P et al.Infection control and hospital epidemiology. 2009, Vol 30, Num 8, pp 746-752, issn 0899-823X, 7 p.Article

Use of monte carlo simulation to assess the pharmacodynamics of β-lactams against Pseudomonas aeruginosa infections in children : A report from the OPTAMA programELLIS, Jennifer M; KUTI, Joseph L; NICOLAU, David P et al.Clinical therapeutics. 2005, Vol 27, Num 11, pp 1820-1830, issn 0149-2918, 11 p.Article

Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessmentDERYKE, C. Andrew; KUTI, Joseph L; NICOLAU, David P et al.Diagnostic microbiology and infectious disease. 2007, Vol 58, Num 3, pp 337-344, issn 0732-8893, 8 p.Article

Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniaeSUN, Heather K; NICOLAU, David P; KUTI, Joseph L et al.Chest. 2006, Vol 130, Num 3, pp 807-814, issn 0012-3692, 8 p.Article

Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated PneumoniaMACVANE, Shawn H; KUTI, Joseph L; NICOLAU, David P et al.Antimicrobial agents and chemotherapy. 2014, Vol 58, Num 3, pp 1359-1364, issn 0066-4804, 6 p.Article

Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia ModelCRANDON, Jared L; KUTI, Joseph L; NICOLAU, David P et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 12, pp 5115-5119, issn 0066-4804, 5 p.Article

The Current State of Multidrug-Resistant Gram-Negative Bacilli in North America : Insights from the Society of Infectious Diseases PharmacistsNICASIO, Anthony M; KUTI, Joseph L; NICOLAU, David P et al.Pharmacotherapy. 2008, Vol 28, Num 2, pp 235-249, issn 0277-0008, 15 p.Article

Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infectionsCHONGHUA LI; XIAOLI DU; KUTI, Joseph L et al.Antimicrobial agents and chemotherapy. 2007, Vol 51, Num 5, pp 1725-1730, issn 0066-4804, 6 p.Article

Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002KUTI, Joseph L; NIGHTINGALE, Charles H; NICOLAU, David P et al.Antimicrobial agents and chemotherapy. 2004, Vol 48, Num 7, pp 2464-2470, issn 0066-4804, 7 p.Article

In Vitro Pharmacodynamics of Vancomycin and Cefazolin Alone and in Combination against Methicillin-Resistant Staphylococcus aureusHAGIHARA, Mao; WISKIRCHEN, Dora E; KUTI, Joseph L et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 1, pp 202-207, issn 0066-4804, 6 p.Article

Clinical Pharmacodynamics of Cefepime in Patients Infected with Pseudomonas aeruginosaCRANDON, Jared L; BULIK, Catharine C; KUTI, Joseph L et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 3, pp 1111-1116, issn 0066-4804, 6 p.Article

In Vitro Activity and Pharmacodynamics of Commonly Used Antibiotics Against Adult Systemic Isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US HospitalsEAGYE, Kathryn J; KUTI, Joseph L; SUTHERLAND, Christina A et al.Clinical therapeutics. 2009, Vol 31, Num 11, pp 2678-2688, issn 0149-2918, 11 p.Article

Empiric therapy for secondary peritonitis : A pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/ tazobactam, and tigecycline using monte carlo simulationEAGYE, Kathryn J; KUTI, Joseph L; DOWZICKY, Michael et al.Clinical therapeutics. 2007, Vol 29, Num 5, pp 889-899, issn 0149-2918, 11 p.Article

Clinical implications of extended spectrum β-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectivenessKOTAPATI, Srividya; KUTI, Joseph L; NIGHTINGALE, Charles H et al.The Journal of infection. 2005, Vol 51, Num 3, pp 211-217, issn 0163-4453, 7 p.Article

Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006 : a report from the OPTAMA programKOOMANACHAI, Pornpan; CRANDON, Jared L; KUTI, Joseph L et al.International journal of antimicrobial agents (Print). 2009, Vol 33, Num 4, pp 348-353, issn 0924-8579, 6 p.Article

Optimising dosing strategies of antibacterials utilising pharmacodynamic principles : Impact on the development of resistanceANDREW DERYKE, C; SU YOUNG LEE; KUTI, Joseph L et al.Drugs (Basel). 2006, Vol 66, Num 1, pp 1-14, issn 0012-6667, 14 p.Article

Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oralKUTI, Joseph L; LE, Thuy N; NIGHTINGALE, Charles H et al.American journal of health-system pharmacy. 2002, Vol 59, Num 22, pp 2209-2215, issn 1079-2082, 7 p.Conference Paper

In Vitro Pharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumanniiHAGIHARA, Mao; HOUSMAN, Seth T; NICOLAU, David P et al.Antimicrobial agents and chemotherapy. 2014, Vol 58, Num 2, pp 874-879, issn 0066-4804, 6 p.Article

Cost-Effectiveness of Telavancin versus Vancomycin for Treatment of Complicated Skin and Skin Structure InfectionsLAOHAVALEESON, Somvadee; BARRIERE, Steven L; NICOLAU, David P et al.Pharmacotherapy. 2008, Vol 28, Num 12, pp 1471-1482, issn 0277-0008, 12 p.Article

Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infectionsKUTI, Joseph L; ONG, Christine; LO, Mathew et al.International journal of antimicrobial agents. 2006, Vol 28, Num 1, pp 62-68, issn 0924-8579, 7 p.Article